Summit Therapeutics (SMMT) Misses Q4 EPS by 21c

Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.29), GBP0.21 worse than the analyst estimate of (GBP0.08).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker